Feature | Published:

Biomanufacturing, from bust to boom...to bubble?

Nature Biotechnology volume 22, pages 13651372 (2004) | Download Citation


Has a worldwide shortage in biomanufacturing capacity turned to a glut in just 4 years? A building boom and advances in technology threaten to derail adoption of potentially cheaper transgenic manufacturing platforms.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Industry Analysis: The State of Biologics Manufacturing (J.P. Morgan Securities, New York, March 12, 2001).

  2. 2.

    Biotechnology Industry Organization. Advantages of plants to produce therapeutic proteins (BIO, Washington, DC, 2004).

  3. 3.

    Maximizing outsourced biopharma production. Contract Pharma, 72–78 (June 2004).

Download references

Author information


  1. Karl A. Thiel is a freelance writer based in Portland, Oregon, USA.

    • Karl A Thiel


  1. Search for Karl A Thiel in:

About this article

Publication history




Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing